Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation

Journal of Infection and Chemotherapy

Volumn 18, Issue 2, 2012, Pages 169-174

  Yoshino, Munehiro ^a   Yagura, Hiroki ^a   Kushida, Hiroyuki ^a   Yonemoto, Hitoshi ^a   Bando, Hiroki ^a   Ogawa, Yoshihiko ^a   Yajima, Keishiro ^a   Kasai, Daisuke ^a   Taniguchi, Tomohiro ^a   Watanabe, Dai ^a   Nishida, Yasuharu ^a   Kuwahara, Takeshi ^b   Uehira, Tomoko ^a   Shirasaka, Takuma ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b National Hospital Organization Minami Kyoto Hospital   (Japan)

Author keywords

Antiretroviral therapy; HIV; Nephrotoxicity; Renal function; Reversibility; Tenofovir

Indexed keywords

TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPANESE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

EID: 84863312055     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0310-6     Document Type: Article

References (18)

1. The Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. http://www.aidsinfo.nih.gov/ (revised on January 10).
2. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18:1074-6.
3. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006; 42:283-90.
4. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-304.
5. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89:513-9.
6. Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J AIDS. 2009;51:258-63.
7. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273-81.
8. Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, et al. CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother. 2008;62:6-11.
9. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331-3.
10. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovirrelated nephrotoxicity: case report and review of the literature. Pharmacotherapy. 2004;24:415-8.
11. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect. 2005;51:E61-5.
12. Kapitsinou PP, Ansari N. Acute renal failure in an AIDS patient on tenofovir: a case report. J Med Case Rep. 2008;2:94.
13. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retrovir. 2009;25:387-94.
14. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J AIDS. 2010;55:78-81.
15. Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with lowbody weight. Curr HIV Res. 2010;8:504-9.
16. Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6:e22661.
17. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-85.
18. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS. 2006;20:561-5.